Short Interest in MDxHealth SA (NASDAQ:MDXH) Decreases By 42.6%

MDxHealth SA (NASDAQ:MDXH) saw a large drop in short interest during the month of December. As of December 15th, there was short interest totaling 15,027 shares, a drop of 42.6% from the November 30th total of 26,198 shares. Based on an average daily volume of 122,196 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the shares of the company are sold short. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 122,196 shares, the days-to-cover ratio is currently 0.1 days.

Hedge Funds Weigh In On MDxHealth

Hedge funds have recently added to or reduced their stakes in the business. GSA Capital Partners LLP acquired a new position in MDxHealth during the third quarter worth about $48,000. Lido Advisors LLC purchased a new position in shares of MDxHealth during the 3rd quarter worth approximately $48,000. Jefferies Financial Group Inc. acquired a new position in shares of MDxHealth during the 3rd quarter worth approximately $53,000. Hudson Bay Capital Management LP purchased a new stake in MDxHealth in the 3rd quarter valued at approximately $70,000. Finally, Bank of America Corp DE lifted its stake in MDxHealth by 5,164.0% in the 3rd quarter. Bank of America Corp DE now owns 15,055 shares of the company’s stock valued at $70,000 after buying an additional 14,769 shares in the last quarter.

MDxHealth Price Performance

Shares of MDXH traded down $0.06 on Friday, reaching $3.41. The stock had a trading volume of 42,254 shares, compared to its average volume of 110,342. MDxHealth has a twelve month low of $1.35 and a twelve month high of $5.33. The firm has a market capitalization of $161.26 million, a PE ratio of -5.33 and a beta of 1.59. The firm has a 50-day moving average of $3.84 and a 200 day moving average of $3.37. The company has a quick ratio of 1.02, a current ratio of 1.14 and a debt-to-equity ratio of 13.81.

MDxHealth (NASDAQ:MDXH) last posted its earnings results on Wednesday, November 12th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The firm had revenue of $27.43 million for the quarter, compared to analysts’ expectations of $24.11 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 30.50%. Sell-side analysts expect that MDxHealth will post -1.15 EPS for the current year.

Analyst Upgrades and Downgrades

MDXH has been the subject of several recent research reports. Lake Street Capital increased their price target on MDxHealth from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Weiss Ratings restated a “sell (e+)” rating on shares of MDxHealth in a research note on Wednesday, October 8th. Wall Street Zen raised shares of MDxHealth to a “hold” rating in a report on Saturday, August 30th. BTIG Research reissued a “buy” rating and set a $7.00 price target on shares of MDxHealth in a report on Tuesday, December 23rd. Finally, TD Cowen increased their price target on shares of MDxHealth from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.75.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.